Stockscreener 앱 받기
12.53
3.84%
-0.50
전일 마감가:
$13.03
열려 있는:
$13.07
하루 거래량:
504.87K
Relative Volume:
1.04
시가총액:
$199.74M
수익:
$13.11M
순이익/손실:
$-124.02M
주가수익비율:
-0.8786
EPS:
-14.261
순현금흐름:
$-107.25M
1주 성능:
+1.54%
1개월 성능:
+14.32%
6개월 성능:
-19.06%
1년 성능:
-70.42%
1일 변동 폭
$12.36
$13.15
1주일 범위
$12.10
$13.19
52주 변동 폭
$10.03
$69.97
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.53 | 199.74M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr
Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria
Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget
Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha
Tonix enrolls first patient in Phase 2 depression study - grafa.com
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - The Manila Times
Tonix Pharma Begins Pivotal Phase 2 Depression Trial - TipRanks
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder - Quiver Quantitative
Tonix Pharmaceuticals Announces First Patient Enrolled in - GlobeNewswire
Tonix starts Phase 2 depression trial for TNX-102 SL - Stock Titan
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (DUS:TPM0) - TradingView
Enterprise value to revenue forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (NASDAQ:TNXP) - TradingView
Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (FWB:TPM0) - TradingView
Enterprise value to EBIT forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Price to sales forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Enterprise value to EBITDA forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView
Tonix Pharmaceuticals (TNXP) Receives Strong Buy Rating with $26 Target - GuruFocus
TNXP Forecast — Price Target — Prediction for 2027 - TradingView
TNXP Initiated Coverage by Raymond James -- Price Target Set at $26 - GuruFocus
Raymond James initiates Tonix Pharma stock coverage with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print - Stocktwits
Tonix Pharmaceuticals Holding Corp (TNXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trading the Move, Not the Narrative: (TNXP) Edition - Stock Traders Daily
Millennium Management LLC Increases Stake in Tonix Pharmaceuticals Holding Corp - GuruFocus
Millennium Management LLC Increases Stake in Tonix Pharmaceutica - GuruFocus
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Institutional Confidence - TradingKey
Tonix Pharmaceuticals Holding Corp - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):